Close this search box.

A randomised trial of weekly cetuximab and radiation versus weekly cisplatin and radiation in good prognosis loco regionally advanced HPV-associated oropharyngeal squamous cell carcinoma

Primary Sponsor

Trans Tasman Radiation Oncology Group (TROG)

Final Accrual


Closing Date of Accrual

7th June 2018

Trial Chairperson

Prof Danny Rischin and A/Prof June Corry

Trial Contact

Clinical Trial Registration

Related Post

18 October, 2022

NINJA Radiation Therapy Trial participant tells his journey to treatment

The journey to becoming the 200th participant for the

6 September, 2022

The gift that kept on giving

The NewyWay Coffee Collaboration Newcastle marketing agency, The Marketing